一分钟看懂
这是一项关于Lung Non-Small Cell Carcinoma的III 期研究，登记的药物或干预包括Biospecimen Collection；Computed Tomography；Durvalumab；Patient Observation；Questionnaire Administration，当前状态为招募中。登记地点显示中国Jonesboro、Beverly Hills、Dublin、Fremont等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biospecimen Collection；Computed Tomography；Durvalumab；Patient Observation；Questionnaire Administration · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro · Jonesboro
- Tower Cancer Research Foundation · Beverly Hills
- Kaiser Permanente Dublin · Dublin
- Kaiser Permanente-Fremont · Fremont
- Kaiser Permanente Fresno Orchard Plaza · Fresno
- UC San Diego Moores Cancer Center · La Jolla
- Veterans Affairs Loma Linda Healthcare System · Loma Linda
- Cedars-Sinai Medical Center · Los Angeles
- Kaiser Permanente- Modesto MOB II · Modesto
- Kaiser Permanente-Oakland · Oakland
- Kaiser Permanente-Roseville · Roseville
- Kaiser Permanente Downtown Commons · Sacramento
- University of California Davis Comprehensive Cancer Center · Sacramento
- Kaiser Permanente-South Sacramento · Sacramento
- Kaiser Permanente-San Francisco · San Francisco
- Kaiser Permanente-Santa Teresa-San Jose · San Jose
- Kaiser Permanente San Leandro · San Leandro
- Kaiser San Rafael-Gallinas · San Rafael
- Kaiser Permanente Medical Center - Santa Clara · Santa Clara
- Kaiser Permanente-Santa Rosa · Santa Rosa
- Kaiser Permanente-South San Francisco · South San Francisco
- Torrance Memorial Physician Network - Cancer Care · Torrance
- Kaiser Permanente-Vallejo · Vallejo
- Kaiser Permanente-Walnut Creek · Walnut Creek
- Kaiser Permanente-Franklin · Denver
- Saint Mary's Hospital and Regional Medical Center · Grand Junction
- Kaiser Permanente-Rock Creek · Lafayette
- Kaiser Permanente-Lone Tree · Lone Tree
- Hartford HealthCare - Avon · Avon
- Hartford Hospital · Hartford
公开的入选条件
- * Participants must have histologically or cytological confirmed diagnosis of clinical stage II-IIIB (excluding clinical N3 disease) non-small cell lung cancer (NSCLC)
- * Participants must have had a complete (R0) resection of NSCLC (with appropriate lymph node sampling as defined by the National Comprehensive Cancer Network \[NCCN\] guidelines) within 84 days (12 weeks) prior to randomization. Acceptable types of surgical re
- Note the NCCN guidelines: N1 and N2 node resection and mapping is a routine component of lung cancer resections. It is recommended at a minimum one N1 and three N2 stations is sampled or complete lymph node dissection. Formal ipsilateral mediastinal lymph node
- * Participants must have a pathologic complete response (pCR) (no viable tumor in the resected specimen or lymph nodes), as determined by local pathology review
- * Participants must have a PD-L1 status result (e.g. \[\< 1% versus \>= 1% or unknown\])
- * Participants must not have known EGFR mutations, or ALK gene fusion
- * Participants must have received at least two cycles of neoadjuvant platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy. The neoadjuvant treatment must be Food and Drug Administration (FDA) approved and standard of care as listed in NCCN guideline
- * Participants must not be planning to receive any concurrent non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for NSCLC treatment while receiving treatment on this study
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06498635；登记信息更新于 2026-09-17。